"Oncology & Hematology Clinic"

During the past decade, University Cancer and Blood Center, LLC conducted 111 clinical trials. In the 10-year time frame, 111 clinical trials started and 78 clinical trials were completed, i.e. on average, 70.3% percent of trials that started reached the finish line to date. In the past 5 years, 48 clinical trials started and 48 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University Cancer and Blood Center, LLC" #1 sponsor was "National Cancer Institute (NCI)" with 32 trials, followed by "SWOG Cancer Research Network" with 18 trials sponsored, "Hoffmann-La Roche" with 11 trials sponsored, "Bristol-Myers Squibb" with 8 trials sponsored and "Novartis Pharmaceuticals" with 8 trials sponsored. Other sponsors include 86 different institutions and companies that sponsored additional 55 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University Cancer and Blood Center, LLC" #1 collaborator was "National Cancer Institute (NCI)" with 31 trials as a collaborator, "NRG Oncology" with 6 trials as a collaborator, "Cancer and Leukemia Group B" with 4 trials as a collaborator, "NCIC Clinical Trials Group" with 4 trials as a collaborator and "SWOG Cancer Research Network" with 4 trials as a collaborator. Other collaborators include 36 different institutions and companies that were collaborators in the rest 32 trials.

According to Clinical.Site data, the most researched conditions in "University Cancer and Blood Center, LLC" are "Breast Cancer" (19 trials), "Non-Small Cell Lung Cancer" (10 trials), "Carcinoma, Non-Small-Cell Lung" (8 trials), "Recurrent Squamous Cell Lung Carcinoma" (8 trials) and "Melanoma" (7 trials). Many other conditions were trialed in "University Cancer and Blood Center, LLC" in a lesser frequency.

Most popular intervention types in "University Cancer and Blood Center, LLC" are "Drug" (148 trials), "Other" (54 trials), "Biological" (39 trials), "Procedure" (16 trials) and "Radiation" (5 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (27 trials), "Nivolumab" (17 trials), "Docetaxel" (16 trials), "Carboplatin" (15 trials) and "Paclitaxel" (15 trials). Other intervention names were less common.

The vast majority of trials in "University Cancer and Blood Center, LLC" are 140 trials for "All" genders, 24 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "University Cancer and Blood Center, LLC". undefined are not yet recruiting, 29 are recruiting, 55 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 62 completed trials in University Cancer and Blood Center, LLC, undefined suspended trials, and 16 terminated clinical trials to date.

Out of the total trials that were conducted in University Cancer and Blood Center, LLC, 12 "Phase 1" clinical trials were conducted, 79 "Phase 2" clinical trials and 82 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".